Macrocyclics continues to lead in the design and development of innovative chelating agent and bioconjugation technologies in ways that will make a difference for treatment of life threatening disease and improvement in human health. The pioneering members of the Macrocyclics team – its founders, partners, customers, scientific advisors, management team and staff – are proud to be at the cutting edge of this new frontier in targeted therapeutic medicine, poised to launch innovative and powerful new medicines to combat cancer and life threatening ailments. We are not only creating new tools at the molecular level for advancing medicine, but also increasing the awareness of the critical role that targeted therapies will play in the future. As you explore the Macrocyclics website, I hope you will share our view that the products and services offered by this company are not only remarkable from a scientific perspective, but also they play a major role in accelerating the process of innovation and discovery through the efforts of customers and partners.

But in fact, what makes Macrocyclics so special?

None of Macrocyclics’ achievements would have been possible without the very special team of founders and people who drive forward the work at Macrocyclics.

We are fortunate to have world class chemistry/bioconjugation experts and a management team that knows how to manage, motivate and share their unique know-how with customers. At Macrocyclics, everyone performs to the highest professional standards, both in terms of organization and scientific methodology, quality and responsiveness. But most significantly, they all have a passionate commitment to Macrocyclics and AREVA Med, and the ambitious and global goals that we have assessed together.

I would like to congratulate the team that “makes it happen” and all our partners who together allow our CEO to say with confidence that Macrocyclics is well on the way to fulfilling its first class service to all our worldwide customers.

Front row (left to right): Dean Sherry (Macrocyclics Founder), Garry Kiefer (CEO Macrocyclics), Patrick Bourdet (President & CEO of AREVA Med); Back; Jeff Stark, Tom Pennigton, Geoff Wilde

We are extremely excited to join the dynamic team at AREVA Med. The synergy with our chelation chemistry expertise at Macrocyclics and the world class isotope production capabilities of AREVA Med is a perfect match to accelerate the introduction of new targeted therapies for clinical applications.

The acquisition of our company by AREVA Med comes at an ideal time when the therapeutic power of lead-212 has been proven. By bringing our expertise with chelators to the unique competencies of AREVA Med, we will develop new powerful and targeted treatments for patients. With AREVA Med’s support, we will be able to offer an even broader range of services to our clients,” added Garry Kiefer, CEO of Macrocyclics.

Read the official AREVA Med press release here [PDF link].